Literature DB >> 15855637

Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis.

David C J Howell1, Robin H Johns, Joseph A Lasky, Bin Shan, Chris J Scotton, Geoffrey J Laurent, Rachel C Chambers.   

Abstract

Activation of the coagulation cascade is commonly observed in the lungs of patients with both acute and chronic inflammatory and fibrotic lung disorders, as well as in animal models of these disorders. The aim of this study was to examine the contribution of the major thrombin receptor, proteinase-activated receptor-1 (PAR-1), during the acute inflammatory and chronic fibrotic phases of lung injury induced by intratracheal instillation of bleomycin in mice. Inflammatory cell recruitment and increases in bronchoalveolar lavage fluid (BALF) protein were attenuated by 56 +/- 10% (P < 0.05) and 53 +/- 12% (P < 0.05), respectively, in PAR-1-deficient (PAR-1-/-) mice compared with wild-type (WT) mice. PAR-1-/- mice were also protected from bleomycin-induced pulmonary fibrosis with total lung collagen accumulation reduced by 59 +/- 5% (P < 0.05). The protection afforded by PAR-1 deficiency was accompanied by significant reductions in pulmonary levels of the potent PAR-1-inducible proinflammatory and profibrotic mediators, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor-beta-1 (TGF-beta1), and connective tissue growth factor/fibroblast-inducible secreted protein-12 (CTGF/FISP12). In addition, PAR-1 was highly expressed in inflammatory and fibroproliferative lesions in lung sections obtained from patients with fibrotic lung disease. These data show for the first time that PAR-1 signaling plays a key role in experimentally induced lung injury, and they further identify PAR-1 as one of the critical receptors involved in orchestrating the interplay between coagulation, inflammation, and remodeling in response to tissue injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855637      PMCID: PMC1606391          DOI: 10.1016/S0002-9440(10)62354-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  79 in total

1.  Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.

Authors:  Claudia K Derian; Bruce P Damiano; Michael F Addo; Andrew L Darrow; Michael R D'Andrea; Mark Nedelman; Han-Cheng Zhang; Bruce E Maryanoff; Patricia Andrade-Gordon
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

Review 2.  Protein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury.

Authors:  Alma Siflinger-Birnboim; Arnold Johnson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-03       Impact factor: 5.464

3.  Thrombin stimulates production of fibronectin by human proximal tubular epithelial cells via a transforming growth factor-beta-dependent mechanism.

Authors:  Kenichi Shirato; Hiroshi Osawa; Mitsuaki Kaizuka; Norio Nakamura; Toshiyuki Sugawara; Masayuki Nakamura; Michiko Tamura; Hideaki Yamabe; Ken Okumura
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

4.  Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia.

Authors:  Rafal Pawlinski; Brian Pedersen; Gernot Schabbauer; Michael Tencati; Todd Holscher; William Boisvert; Patricia Andrade-Gordon; Rolf Dario Frank; Nigel Mackman
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

Review 5.  Specificity of coagulation factor signaling.

Authors:  W Ruf; A Dorfleutner; M Riewald
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

6.  PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation.

Authors:  Stefano Fiorucci; Elisabetta Antonelli; Eleonora Distrutti; Beatrice Severino; Roviezzo Fiorentina; Monia Baldoni; Giuseppe Caliendo; Vincenzo Santagada; Antonio Morelli; Giuseppe Cirino
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

7.  Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas.

Authors:  Enjing Jin; Masakazu Fujiwara; Xin Pan; Mohammad Ghazizadeh; Satoru Arai; Yoshiharu Ohaki; Keiko Kajiwara; Tamiko Takemura; Oichi Kawanami
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis.

Authors:  Mehrnaz Gharaee-Kermani; Robert E McCullumsmith; Israel F Charo; Steven L Kunkel; Sem H Phan
Journal:  Cytokine       Date:  2003-12-21       Impact factor: 3.861

9.  Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis.

Authors:  Philippe Bonniaud; Peter J Margetts; Martin Kolb; Thomas Haberberger; Margaret Kelly; Jennifer Robertson; Jack Gauldie
Journal:  Am J Respir Crit Care Med       Date:  2003-06-19       Impact factor: 21.405

10.  Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits.

Authors:  Andreas Günther; Norbert Lübke; Monika Ermert; Ralph T Schermuly; Norbert Weissmann; Andreas Breithecker; Philipp Markart; Clemens Ruppert; Karin Quanz; Leander Ermert; Friedrich Grimminger; Werner Seeger
Journal:  Am J Respir Crit Care Med       Date:  2003-12-01       Impact factor: 21.405

View more
  72 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 2.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 3.  Mechanisms of alveolar epithelial injury, repair, and fibrosis.

Authors:  Rachel C Chambers; Paul F Mercer
Journal:  Ann Am Thorac Soc       Date:  2015-03

4.  Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis.

Authors:  Keren Borensztajn; Paul Bresser; Chris van der Loos; Ilze Bot; Bernt van den Blink; Michael A den Bakker; Joost Daalhuisen; Angelique P Groot; Maikel P Peppelenbosch; Jan H von der Thüsen; C Arnold Spek
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

5.  Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury.

Authors:  Barry S Shea; Sarah F Brooks; Benjamin A Fontaine; Jerold Chun; Andrew D Luster; Andrew M Tager
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

Review 6.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

Review 7.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

8.  Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q).

Authors:  Ming Yan Xu; Joanne Porte; Alan J Knox; Paul H Weinreb; Toby M Maher; Shelia M Violette; Robin J McAnulty; Dean Sheppard; Gisli Jenkins
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14

Review 10.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.